Study on the Impurity Profile and Its Correlation With the Production Process in the Estazolam API and Tablets

Area of Science:

• Pharmaceutical Chemistry
• Analytical Chemistry

Background:

• Estazolam, a widely used benzodiazepine, has generic formulations on the Chinese market.
• Current generic estazolam products necessitate standardized impurity analysis methods for active pharmaceutical ingredient (API) and tablets.

Purpose of the Study:

• Develop and validate sensitive analytical methods (HPLC-UV, LC-MS/MS) for estazolam impurities.
• Quantify impurity levels and profiles in generic estazolam tablets and APIs.
• Correlate impurity profiles with manufacturing processes to ensure drug quality and safety.

Main Methods:

• High-performance liquid chromatography with ultraviolet detection (HPLC-UV) for quantitative impurity analysis.
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for impurity profiling and structural identification.
• Method validation according to International Council for Harmonisation (ICH) guidelines.

Main Results:

• Identified two USP-listed process impurities, two unknown process impurities, and one non-pharmacopeial degradation product.
• Successfully separated and preliminarily characterized unknown impurities.
• Established impurity profiles for estazolam API and generic tablet formulations.

Conclusions:

• Three API process impurities significantly influence preparation impurity profiles.
• Impurity levels are closely linked to API synthesis routes and purification methods.
• API manufacturers must optimize purification to control impurities, ensuring estazolam drug safety.